Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4.65	2.86	2.02	2.88	6.95
Short-Term Investments	10.68	9.78	11.77	31.93	43.94
Cash & Short-Term Investments	15.33	12.64	13.79	34.82	50.89
Cash Growth	21.27%	-8.29%	-60.41%	-31.58%	-32.59%
Other Receivables	0.21	0.17	0.16	0.08	0.07
Receivables	0.21	0.17	0.16	0.08	0.07
Prepaid Expenses	0.46	0.32	0.67	1.05	0.75
Restricted Cash	0.12	0.12	0.11	0.11	0.11
Total Current Assets	16.12	13.24	14.72	36.05	51.81
Property, Plant & Equipment	-	0.13	0.34	0.55	0.57
Long-Term Investments	2.12	3.27	1.5	-	-
Total Assets	18.5	16.63	16.56	36.61	52.38
Accounts Payable	1.31	1.88	2.56	4.87	7.05
Accrued Expenses	0.86	0.83	-	-	-
Current Portion of Leases	-	0.04	0.17	0.21	0.2
Other Current Liabilities	0.01	-	0.36	0.8	0.76
Total Current Liabilities	2.17	2.75	3.09	5.88	8.01
Long-Term Leases	-	-	0.04	0.23	0.22
Total Liabilities	2.17	2.75	3.14	6.11	8.23
Common Stock	0.74	0.21	0.07	0.07	0.06
Additional Paid-In Capital	216.47	207.08	200.14	198.77	179.53
Retained Earnings	-200.47	-192.95	-186.04	-168.17	-135.71
Comprehensive Income & Other	-0.42	-0.45	-0.75	-0.17	0.27
Shareholders' Equity	16.33	13.88	13.42	30.5	44.15
Total Liabilities & Equity	18.5	16.63	16.56	36.61	52.38
Total Debt	-	0.04	0.22	0.44	0.42
Net Cash (Debt)	15.33	12.6	13.57	34.38	50.47
Net Cash Growth	21.66%	-7.13%	-60.53%	-31.88%	-32.84%
Net Cash Per Share	16.47	54.60	97.14	251.58	426.87
Filing Date Shares Outstanding	2.26	0.5	0.14	0.14	0.14
Total Common Shares Outstanding	1.66	0.42	0.14	0.14	0.12
Working Capital	13.95	10.49	11.63	30.18	43.8
Book Value Per Share	9.81	33.01	95.87	218.80	372.67
Tangible Book Value	16.33	13.88	13.42	30.5	44.15
Tangible Book Value Per Share	9.81	33.01	95.87	218.80	372.67
Machinery	0.79	0.79	0.79	0.79	0.79
Leasehold Improvements	0.24	0.24	0.24	0.23	0.22

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q